These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 15746055)
1. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Suzuki H; Graziano DF; McKolanis J; Finn OJ Clin Cancer Res; 2005 Feb; 11(4):1521-6. PubMed ID: 15746055 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer. Egloff AM; Weissfeld J; Land SR; Finn OJ Ann N Y Acad Sci; 2005 Dec; 1062():29-40. PubMed ID: 16461786 [TBL] [Abstract][Full Text] [Related]
3. CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53. Sørensen RB; Andersen RS; Svane IM; Engell-Noerregaard L; Hadrup SR; Balslev E; Andersen MH; thor Straten P Clin Cancer Res; 2009 Mar; 15(5):1543-9. PubMed ID: 19223507 [TBL] [Abstract][Full Text] [Related]
4. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer. Cooper WA; Kohonen-Corish MR; McCaughan B; Kennedy C; Sutherland RL; Lee CS Histopathology; 2009 Jul; 55(1):28-36. PubMed ID: 19614764 [TBL] [Abstract][Full Text] [Related]
5. Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer. Olson BM; McNeel DG Prostate; 2007 Dec; 67(16):1729-39. PubMed ID: 17879963 [TBL] [Abstract][Full Text] [Related]
6. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Looi K; Megliorino R; Shi FD; Peng XX; Chen Y; Zhang JY Oncol Rep; 2006 Nov; 16(5):1105-10. PubMed ID: 17016600 [TBL] [Abstract][Full Text] [Related]
7. Expression and immunogenicity of a tumor-associated antigen, 90K/Mac-2 binding protein, in lung carcinoma. Ozaki Y; Kontani K; Hanaoka J; Chano T; Teramoto K; Tezuka N; Sawai S; Fujino S; Yoshiki T; Okabe H; Ohkubo I Cancer; 2002 Nov; 95(9):1954-62. PubMed ID: 12404290 [TBL] [Abstract][Full Text] [Related]
8. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Schmielau J; Finn OJ Cancer Res; 2001 Jun; 61(12):4756-60. PubMed ID: 11406548 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of cyclin B1 protein expression in colorectal cancer. Grabsch H; Lickvers K; Hansen O; Takeno S; Willers R; Stock W; Gabbert HE; Mueller W Am J Clin Pathol; 2004 Oct; 122(4):511-6. PubMed ID: 15487447 [TBL] [Abstract][Full Text] [Related]
10. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Zhang H; Stephens LC; Kumar R Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771 [TBL] [Abstract][Full Text] [Related]
11. The specific immune response to tumor antigen CP1 and its correlation with improved survival in colon cancer patients. Liu FF; Dong XY; Pang XW; Xing Q; Wang HC; Zhang HG; Li Y; Yin YH; Fant M; Ye YJ; Shen DH; Zhang Y; Wang S; Chen WF Gastroenterology; 2008 Apr; 134(4):998-1006. PubMed ID: 18395081 [TBL] [Abstract][Full Text] [Related]
12. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. Ersvaer E; Zhang JY; McCormack E; Olsnes A; Anensen N; Tan EM; Gjertsen BT; Bruserud O Eur J Haematol; 2007 Sep; 79(3):210-25. PubMed ID: 17655707 [TBL] [Abstract][Full Text] [Related]
13. Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer. Zheng H; Hu W; Deavers MT; Shen DY; Fu S; Li YF; Kavanagh JJ Am J Obstet Gynecol; 2009 Oct; 201(4):367.e1-6. PubMed ID: 19608149 [TBL] [Abstract][Full Text] [Related]
14. Increased levels of a 21-kDa protein in the circulation of tumor-bearing patients. Shalitin C; Epelbaum R; Moskovitz B; Segal R; Valansi C; Werner M; Livne PM Cancer Detect Prev; 1994; 18(5):357-65. PubMed ID: 7812982 [TBL] [Abstract][Full Text] [Related]
15. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Domschke C; Schuetz F; Ge Y; Seibel T; Falk C; Brors B; Vlodavsky I; Sommerfeldt N; Sinn HP; Kühnle MC; Schneeweiss A; Scharf A; Sohn C; Schirrmacher V; Moldenhauer G; Momburg F; Beckhove P Cancer Res; 2009 Nov; 69(21):8420-8. PubMed ID: 19843863 [TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Fu SL; Pierre J; Smith-Norowitz TA; Hagler M; Bowne W; Pincus MR; Mueller CM; Zenilman ME; Bluth MH Clin Exp Immunol; 2008 Sep; 153(3):401-9. PubMed ID: 18803764 [TBL] [Abstract][Full Text] [Related]
17. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Egloff AM; Vella LA; Finn OJ Cancer Res; 2006 Jan; 66(1):6-9. PubMed ID: 16397206 [TBL] [Abstract][Full Text] [Related]
18. CABYR is a novel cancer-testis antigen in lung cancer. Luo C; Xiao X; Liu D; Chen S; Li M; Xu A; Liu J; Gao S; Wu S; He D Clin Cancer Res; 2007 Feb; 13(4):1288-97. PubMed ID: 17317841 [TBL] [Abstract][Full Text] [Related]
19. CDK1-cyclin B1 mediates the inhibition of proliferation induced by omega-3 fatty acids in MDA-MB-231 breast cancer cells. Barascu A; Besson P; Le Floch O; Bougnoux P; Jourdan ML Int J Biochem Cell Biol; 2006 Feb; 38(2):196-208. PubMed ID: 16194618 [TBL] [Abstract][Full Text] [Related]
20. Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Vella LA; Yu M; Fuhrmann SR; El-Amine M; Epperson DE; Finn OJ Proc Natl Acad Sci U S A; 2009 Aug; 106(33):14010-5. PubMed ID: 19666607 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]